CAMRF
Camurus AB (publ)
Set alert
61.75 USD 0.00 0.00%
61.75 Day range 64.00
54.00 52-week range 71.00
- YTD
- -8.01%
- 1 year
- -10.31%
- Open
- 64.00
- Prev close
- 61.75
- Mkt cap
- 3.67B
- Vol
- 200
- Avg vol
- 31
- EPS
- 1.21
- P/E
- 51.03
More statistics
- Low
- 61.75
- High
- 64.00
- Earnings
- Nov 5, 2026
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.4257.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.4257 | — | — | — |
| Jul 15, 2026 | Jun 30, 2026 | 0.3314 | 0.4175 | +0.09 | +25.98% |
| May 12, 2026 | Mar 31, 2026 | 0.3652 | 0.2525 | -0.11 | -30.86% |
| Feb 12, 2026 | Dec 31, 2025 | 0.2561 | 0.1807 | -0.08 | -29.44% |
| Nov 6, 2025 | Sep 30, 2025 | 0.3492 | 0.3463 | 0.00 | -0.83% |
| Jul 17, 2025 | Jun 30, 2025 | 0.3597 | 0.4292 | +0.07 | +19.32% |
News
- Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
- Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript
- Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback
- Camurus announces expansion of Lilly collaboration
- Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript
- Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
- Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript
- Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
- US FDA declines to approve Camurus' rare hormone disorder drug
- New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Your note
Sign in to keep a note on CAMRF — it syncs with the Stock Master app.